You enter the study only after you have completed a previous Novartis-sponsored remibrutinib study and the investigator judges that you may benefit from continued treatment with remibrutinib.

The trial is open-label, which means that the treatment is not hidden and the study drug is known.

The study is for people with chronic spontaneous urticaria, a long-lasting condition that causes hives without a clear trigger.

You take remibrutinib by mouth as a 50 mg film-coated tablet.

The tablet is taken orally, which means swallowed rather than injected or infused.

The trial description does not specify the exact number of doses per day or the exact treatment duration. It only states that the study is for continued treatment with remibrutinib.

You remain on treatment while the study team checks your safety over time.

The main purpose of the trial is to look at long-term safety.

Safety is measured by watching for adverse events and serious adverse events. An adverse event is any unwanted medical problem that happens during the study. A serious adverse event is a more severe medical problem.

Your participation continues until the study period ends or until your treatment is stopped according to the study plan.

The trial is planned to run from 2026-05-20 to 2034-01-09.